Education
About Us
Working with TipRanks
Follow Us
Sunshine Biopharma, Inc. (SBFM)
:SBFM
Total Valuation
Sunshine Biopharma has a market cap or net worth of $4.98M. The enterprise value is -$980.75K.
Market Cap$4.98M
Enterprise Value-$980.75K
Share Statistics
Sunshine Biopharma has 3,635,945 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,635,945
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Sunshine Biopharma’s return on equity (ROE) is -0.21 and return on invested capital (ROIC) is -23.94%.
Return on Equity (ROE)-0.21
Return on Assets (ROA)-0.16
Return on Invested Capital (ROIC)-23.94%
Return on Capital Employed (ROCE)-0.22
Revenue Per Employee463.32K
Profits Per Employee-86.65K
Employee Count52
Asset Turnover0.88
Inventory Turnover2.75
Valuation Ratios
The current PE Ratio of Sunshine Biopharma is -1.47. Sunshine Biopharma’s PEG ratio is 0.02.
PE Ratio-1.47
PS Ratio0.00
PB Ratio0.31
Price to Fair Value0.31
Price to FCF-0.69
Price to Operating Cash Flow-0.75
PEG Ratio0.02
Income Statement
In the last 12 months, Sunshine Biopharma had revenue of 24.09M and earned -4.51M in profits. Earnings per share was -370.41.
Revenue24.09M
Gross Profit8.34M
Operating Income-4.79M
Pretax Income-4.11M
Net Income-4.51M
EBITDA-3.82M
Earnings Per Share (EPS)-370.41
Cash Flow
In the last 12 months, operating cash flow was -11.81M and capital expenditures -2.09M, giving a free cash flow of -13.91M billion.
Operating Cash Flow-11.81M
Free Cash Flow-13.91M
Free Cash Flow per Share-3.82
Dividends & Yields
Sunshine Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.07
52-Week Price Change-91.85%
50-Day Moving Average1.86
200-Day Moving Average2.82
Relative Strength Index (RSI)39.20
Average Volume (3m)2.92M
Important Dates
Sunshine Biopharma upcoming earnings date is May 7, 2025, TBA Not Confirmed.
Last Earnings DateApr 8, 2025
Next Earnings DateMay 7, 2025
Ex-Dividend Date―
Financial Position
Sunshine Biopharma as a current ratio of 4.48, with Debt / Equity ratio of 2.22%
Current Ratio4.48
Quick Ratio3.45
Debt to Market Cap0.00
Net Debt to EBITDA4.09
Interest Coverage Ratio-34.85
Taxes
In the past 12 months, Sunshine Biopharma has paid 395.17K in taxes.
Income Tax395.17K
Effective Tax Rate-0.10
Enterprise Valuation
Sunshine Biopharma EV to EBITDA ratio is 2.36, with an EV/FCF ratio of 0.94.
EV to Sales-0.37
EV to EBITDA2.36
EV to Free Cash Flow0.94
EV to Operating Cash Flow1.03
Balance Sheet
Sunshine Biopharma has $12.21M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$11.65M billion.
Cash & Marketable Securities$12.21M
Total Debt$0.00
Net Cash-$11.65M
Net Cash Per Share-$3.20
Tangible Book Value Per Share$1.62K
Margins
Gross margin is 30.37%, with operating margin of -19.86%, and net profit margin of -18.70%.
Gross Margin30.37%
Operating Margin-19.86%
Pretax Margin-17.06%
Net Profit Margin-18.70%
EBITDA Margin-15.87%
EBIT Margin-16.49%
Analyst Forecast
The average price target for Sunshine Biopharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast44.75%
EPS Growth Forecast86.42%